University of Eastern Finland   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Joensuu; Kuopio Finland (2010)

Organization Overview

First Clinical Trial
2010
NCT00966264
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Marjukka Kolehmainen | University of Eastern Finland | University of Eastern Finland, Institute of Public Health and Clinical Nutrition

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abortion, Spontaneous (Phase 3)

Angina Pectoris (Phase 1)

Coronary Artery Disease (Phase 1)

Coronary Disease (Phase 1)

Diabetes, Gestational (Phase 3)

Fractures, Bone (Phase 4)

Glioblastoma (Phase 2)

Heart Diseases (Phase 1)

Infarction (Phase 1)

Infertility (Phase 3)

Menorrhagia (Phase 3)

Myocardial Infarction (Phase 1)

Myocardial Ischemia (Phase 1)

Neurobehavioral Manifestations (Phase 1)

Osteoarthritis (Phase 4)

Osteoporosis (Phase 4)

Polycystic Ovary Syndrome (Phase 3)

Prostatic Neoplasms (Phase 2)

Schizophrenia (Phase 1)

Stroke (Phase 1)

Syndrome (Phase 3)

Toxemia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial APIs: 25